EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Samia Shabnaz iD, Trang N Nguyen iD, Roy Williams iD, Samuel M Rubinstein iD, Timothy J Garrett iD, Marwa Tantawy iD, Michael G Fradley, Mohammed E Alomar iD, Kenneth H Shain iD, Rachid C Baz iD, Daniel Lenihan, Robert F Cornell iD und 2 weitere

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Samia Shabnaz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Flor…. Hauptthemen laut MEDLINE: Multiple Myeloma, Oligopeptides, Cardiotoxicity, Metabolomics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to evaluate the metabolomic profile of MM patients to identify those at high risk prior to carfilzomib treatment and to explore the mechanisms of carfilzomib‐CVAE to inform potential strategies to protect patients from this cardiotoxicity. Global metabolomic profiling was performed on the baseline and post‐baseline plasma samples of 60 MM patients treated with carfilzomib‐based therapy, including 31 who experienced CVAE, in a prospective cohort study. Baseline metabolites and post‐baseline/baseline metabolite ratios that differ between the CVAE and no‐CVAE patients were identified using unadjusted and adjusted methods. A baseline metabolomic risk score was created to stratify patients. We observed a lower abundance of tauroursodeoxycholic acid (T‐UDCA) in CVAE patients at baseline (odds ratio [OR] = 0.47, 95% confidence interval [CI] = 0.21–0.94, p = 0.044) compared with the no‐CVAE patients. A metabolite risk score was able to stratify patients into three risk groups. The area under the receiver‐operating curve of the model with clinical predictors and metabolite risk score was 0.93. Glycochenodeoxycholic acid (OR = 0.56, 95% CI = 0.31–0.87, p = 0.023) was significantly lower in post‐baseline/baseline ratios of CVAE patients compared with no‐CVAE patients. Following metabolomic analysis, we created a baseline metabolite risk score that can stratify MM patients into different risk groups. The result also provided intriguing clues about the mechanism of carfilzomib‐CVAE and potential cardioprotective strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaOligopeptidesCardiotoxicityMetabolomicsHumansMaleFemaleAgedMiddle AgedProspective StudiesMetabolomeAged, 80 and overRisk Factors

Substanzen

carfilzomibOligopeptides

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Department of Medicine, Division of Hematology, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
  • Cardio-Oncology Center of Excellence, Division of Cardiology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Cape Cardiology Group, Saint Francis Medical Center, Cape Girardeau, Missouri, USA.

ORCID-Profile: Samia Shabnaz, Trang N Nguyen, Roy Williams, Samuel M Rubinstein, Timothy J Garrett, Marwa Tantawy, Mohammed E Alomar, Kenneth H Shain, Rachid C Baz, Robert F Cornell, Qing Lu, Yan Gong

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Shabnaz, S., Nguyen, T. N., Williams, R., Rubinstein, S. M., Garrett, T. J., Tantawy, M., Fradley, M. G., Alomar, M. E., Shain, K. H., Baz, R. C., Lenihan, D., Cornell, R. F., Lu, Q., & Gong, Y. (2024). Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma. Clinical and Translational Science. https://doi.org/10.1111/cts.13828

Vancouver

Shabnaz S, Nguyen TN, Williams R, Rubinstein SM, Garrett TJ, Tantawy M, et al. Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma. Clinical and Translational Science. 2024. doi:10.1111/cts.13828

BibTeX
@article{Shabnaz2024,
  author = {Shabnaz, Samia and Nguyen, Trang N and Williams, Roy and Rubinstein, Samuel M and Garrett, Timothy J and Tantawy, Marwa and Fradley, Michael G and Alomar, Mohammed E and Shain, Kenneth H and Baz, Rachid C and Lenihan, Daniel and Cornell, Robert F and Lu, Qing and Gong, Yan},
  title = {Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13828}
}
Kostenlos starten →